Affinage

Showing PDGFRB — PDGFR is a alias.

PDGFRB

Platelet-derived growth factor receptor beta · UniProt P09619

Length
1106 aa
Mass
124.0 kDa
Annotated
2026-06-10
100 papers in source corpus 31 papers cited in narrative 31 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 10/10 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PDGFRB encodes a receptor tyrosine kinase that, upon PDGF ligand binding, dimerizes and undergoes autophosphorylation to drive the proliferation, migration, and survival of mesenchymal and vascular mural cells (PMID:35946433). PDGFRβ homodimers dimerize rapidly, generate high-amplitude phospho-ERK1/2 and phospho-AKT signaling, and are preferentially recycled to the membrane, in contrast to the faster-degraded PDGFRα homodimers (PMID:35946433). Downstream of the activated receptor, PI3K/AKT signaling drives endothelial progenitor proliferation, migration, and angiogenesis (PMID:22355314), and AKT activation in tumor cells proceeds through a PDGFRβ/ACK1 axis in which the receptor phosphorylates ACK1 at Y635 to enable β-catenin nuclear translocation and cyclin D1 expression (PMID:25257795). Receptor trafficking and signal compartmentalization depend on RhoB, which routes activated PDGFRβ to perinuclear late endosomes and supports nuclear localization of Src, Akt, and ERK (PMID:17951322). The receptor's signaling output is tuned by direct physical partners: integrin α11 binds PDGFRβ ligand-dependently to promote JNK activation and CAF-driven tumor invasion (PMID:31287804), and cadherin-11 binds PDGFRβ to sensitize cells to PDGF-BB and sustain AKT-dependent proliferation and wound healing (PMID:31930567). PDGFRB transcription is repressed by c-Myc through a post-binding, HDAC-dependent step (PMID:15226411), and is positively controlled by synectin via p300-dependent histone modification at its promoter (PMID:29263300); the transcript is also targeted post-transcriptionally by miR-34a (PMID:24638095). Physiologically, PDGFRβ is essential and ligand-specific for pericyte recruitment and vessel stability in vivo (PMID:18827023), and its conserved role in vascular mural cell development is demonstrated in zebrafish, where mutants lack brain pericytes and develop cranial hemorrhage (PMID:34310924); PDGFRβ-positive cells also serve as the renal site of HIF-2α-dependent erythropoietin production (PMID:27220347). Sustained PDGFRβ activity drives pathological fibrosis, as receptor activation alone in renal mesenchymal cells is sufficient to produce mesangioproliferative glomerulonephritis and interstitial fibrosis (PMID:31943786), and conversely promotes cardiomyocyte proliferation and heart regeneration through a PI3K/AKT/EZH2 axis (PMID:31340157). Loss-of-function PDGFRB variants cause primary familial brain calcification (PFBC/IBGC) by abolishing kinase activity, reducing expression, or abrogating PDGF-BB binding (PMID:34494111, PMID:25292412), whereas ligand-independent gain-of-function variants drive infantile myofibromatosis (PMID:28334876, PMID:31017643) and fusiform cerebral aneurysms through constitutive ERK, SRC, AKT, and NF-κB signaling (PMID:31031011, PMID:37315111). Oncogenic PDGFRB fusions (TEL/PDGFRβ, EBF1-PDGFRβ) constitutively activate the kinase to transform hematopoietic cells via JNK/SAPK and STAT5 signaling (PMID:10445851, PMID:28555080).

Mechanistic history

Synthesis pass · year-by-year structured walk · 26 steps
  1. 1999 Medium

    Established that constitutive PDGFRβ kinase activity in an oncogenic fusion couples to a specific stress-kinase cascade, defining how the receptor drives transformation and apoptosis balance.

    Evidence TEL/PDGFRβ fusion expressed in Ba/F3 cells with PDGFRβ kinase inhibitor, dominant-negative MKK4, and PI3K inhibition

    PMID:10445851

    Open questions at the time
    • Mechanism in primary leukemic cells not addressed
    • Relative contribution of JNK vs other pathways to transformation unresolved
  2. 2001 Medium

    Showed PDGFRβ activation is sufficient to drive fibroblast migration, distinguishing its cell-type-specific signaling from antagonistic behavior in smooth muscle.

    Evidence Dominant-negative and antisense PDGFRα constructs in NIH 3T3 cells with PDGF-AA/BB migration assays

    PMID:11401517

    Open questions at the time
    • Molecular basis of additivity with PDGFRα not defined
    • Downstream effectors of migration not mapped
  3. 2004 High

    Defined how PDGFRB transcription is repressed, showing c-Myc occupies the promoter but requires a separable HDAC-dependent step to silence the gene.

    Evidence ChIP in rat fibroblasts with c-Myc mutants and TSA HDAC inhibitor treatment

    PMID:15226411

    Open questions at the time
    • Identity of the HDAC complex recruited not established
    • Generality beyond fibroblasts not tested
  4. 2004 Medium

    Linked PDGFRβ to a developmental role, showing it drives migration/proliferation of mesonephric mesenchymal cells and supports testis cord formation.

    Evidence Immunomagnetic isolation, in vitro assays with MAPK/PI3K inhibitors, urogenital organ culture

    PMID:14996938

    Open questions at the time
    • In vivo genetic requirement not demonstrated
    • Ligand source in vivo not defined
  5. 2007 High

    Identified RhoB as a required trafficking regulator routing activated PDGFRβ to late endosomes and enabling nuclear signaling and proliferation.

    Evidence RhoB knockout vascular smooth muscle cells with re-expression rescue, fractionation, and phosphorylation assays

    PMID:17951322

    Open questions at the time
    • Direct RhoB-PDGFRβ interaction not shown
    • Mechanism of nuclear effector translocation unresolved
  6. 2008 Medium

    Established the ligand-specific in vivo requirement for PDGFRβ in pericyte recruitment and vessel stabilization.

    Evidence Mouse cornea angiogenesis and rat hind-limb ischemia models with anti-PDGFRβ neutralizing antibody and ligand comparisons

    PMID:18827023

    Open questions at the time
    • Single-lab antibody-based loss of function
    • Downstream pericyte recruitment signaling not detailed
  7. 2008 Medium

    Revealed a non-canonical role for PDGFRβ as a cell-surface binding receptor exploited by Chlamydia trachomatis.

    Evidence Drosophila RNAi screen, siRNA and neutralizing antibody in mammalian cells, binding/internalization assays

    PMID:18369471

    Open questions at the time
    • Direct bacterial ligand for PDGFRβ not identified
    • Single-lab characterization
  8. 2012 Medium

    Confirmed that PDGFRβ drives endothelial progenitor angiogenic behavior through a linear PI3K/AKT pathway.

    Evidence PDGFRβ overexpression in EPCs with PDGFR, PI3K, and Akt inhibitors and functional assays

    PMID:22355314

    Open questions at the time
    • Pharmacological rather than genetic dissection
    • In vivo relevance not tested
  9. 2014 High

    Defined a PDGFRβ/ACK1/AKT axis, mapping the specific phosphorylation events that couple the receptor to β-catenin/cyclin D1-driven proliferation in glioma.

    Evidence Co-IP, site-directed mutagenesis (ACK1 Y635F, T325A), signaling and cell cycle assays, patient samples

    PMID:25257795

    Open questions at the time
    • Contribution relative to direct PI3K coupling unresolved
    • In vivo therapeutic implication not tested
  10. 2014 High

    Defined the molecular consequences of IBGC-associated PDGFRB mutations, showing distinct loss-of-function modes from complete kinase dead to selective effector failure.

    Evidence Transfection of L658P and R987W mutants with kinase, multi-effector phosphorylation, and degradation assays

    PMID:25292412

    Open questions at the time
    • Mechanism linking receptor hypofunction to calcification not established
    • In vivo modeling absent
  11. 2014 Medium

    Established post-transcriptional control of PDGFRβ by miR-34a, linking its downregulation to G0/G1 arrest in mesangial cells.

    Evidence Dual-luciferase 3'-UTR reporter, miR-34a gain/loss, cell cycle and pathway analysis, nephritis model

    PMID:24638095

    Open questions at the time
    • In vivo therapeutic relevance limited
    • Single-lab study
  12. 2016 Medium

    Demonstrated genetic interaction between Pdgfra and Pdgfrb in cranial neural crest condensation during palatogenesis.

    Evidence Zebrafish and mouse single/double mutants, pathway inhibition, time-lapse imaging

    PMID:26971580

    Open questions at the time
    • PDGFRβ-specific signaling in neural crest not isolated
    • Molecular basis of condensation failure unresolved
  13. 2016 High

    Identified PDGFRβ-positive cells as the renal HIF-2α-dependent erythropoietin-producing population, situating the receptor as a cell-identity marker for oxygen sensing.

    Evidence Conditional Vhl, Hif1a, Hif2a deletions in PDGFRβ+ cells with EPO measurements and PHD inhibition

    PMID:27220347

    Open questions at the time
    • Whether PDGFRβ signaling itself regulates EPO not addressed
    • Receptor used as marker rather than effector
  14. 2017 Medium

    Showed PDGFRβ is a transcriptional target of JUN/JUNB and a therapeutic vulnerability in NPM-ALK lymphoma.

    Evidence Transcriptional regulation analysis, NPM-ALK transgenic mouse with PDGFRB inhibitor and survival

    PMID:23064464

    Open questions at the time
    • Direct promoter binding by JUN/JUNB not shown
    • Single-lab study
  15. 2017 High

    Distinguished how an oncogenic fusion subverts PDGFRβ, showing its transmembrane domain mediates EBF1 nuclear export and that STAT5 activation drives cytokine-independent B-ALL.

    Evidence TM domain mutagenesis, STAT5 assays, cytokine-independence, in vivo B-ALL model with IKAROS loss

    PMID:28555080

    Open questions at the time
    • Mechanism of TM-domain-driven nuclear export not molecularly resolved
  16. 2017 High

    Revealed dual regulation of receptor abundance by synectin, controlling PDGFRβ transcriptionally via p300-dependent histone modification.

    Evidence Synectin knockdown, ChIP of PDGFRβ promoter, mRNA-seq, fibrosis model

    PMID:29263300

    Open questions at the time
    • Direct synectin recruitment to the promoter not shown
    • Mechanism distinguishing the two receptors incompletely defined
  17. 2017 Medium

    Defined the first ligand-independent gain-of-function PDGFRB mutations transforming fibroblasts in infantile myofibromatosis and their imatinib sensitivity.

    Evidence Sequencing, ligand-independent signaling assays, fibroblast transformation, TKI sensitivity testing

    PMID:28334876

    Open questions at the time
    • In vivo modeling absent
    • D850V resistance mechanism not structurally defined
  18. 2019 High

    Established integrin α11 as a ligand-dependent PDGFRβ partner channeling signaling to JNK and CAF-mediated tumor invasion.

    Evidence Reciprocal Co-IP, pharmacological PDGFRβ/JNK inhibition, invasion assays, MMTV-PyMT mouse model

    PMID:31287804

    Open questions at the time
    • Structural basis of the interaction not defined
    • How α11 biases signaling toward JNK unresolved
  19. 2019 High

    Connected PDGFRβ activation to cardiomyocyte proliferation via a PI3K/AKT/EZH2 epigenetic axis with therapeutic potential.

    Evidence Cardiomyocyte PDGFRβ activation and Ezh2 conditional KO, RNA-seq, H3K27me3 ChIP, AAV9 gene therapy

    PMID:31340157

    Open questions at the time
    • Upstream ligand source in regenerating heart not defined
    • Direct EZH2 target genes incompletely mapped
  20. 2019 Medium

    Defined ligand-independent gain-of-function PDGFRB variants in fusiform cerebral aneurysms with druggable downstream signaling.

    Evidence Paired exome sequencing, variant expression with phosphorylation and ERK/SRC/AKT assays, sunitinib

    PMID:31031011

    Open questions at the time
    • In vivo aneurysm modeling not in this study
    • Single-lab variant characterization
  21. 2019 Medium

    Extended the gain-of-function paradigm to pediatric myofibroma, confirming ligand-independent activation and broad imatinib sensitivity.

    Evidence Targeted deep sequencing and functional gain-of-function/imatinib assays in a cohort

    PMID:31017643

    Open questions at the time
    • Mechanistic depth per variant limited
    • Resistance mechanisms not defined
  22. 2020 High

    Demonstrated PDGFRβ activation alone is sufficient to drive progressive kidney fibrosis through mesangial proliferation and myofibroblast conversion, reversible by inhibition.

    Evidence Transgenic PDGFRβ activation in renal mesenchymal cells, histopathology, expression profiling, PDGFR inhibition

    PMID:31943786

    Open questions at the time
    • Differential glomerular vs interstitial reversibility mechanism unclear
  23. 2020 Medium

    Identified cadherin-11 as a direct PDGFRβ partner that markedly sensitizes cells to PDGF-BB and is required for AKT-dependent wound healing.

    Evidence Co-IP, dose-response proliferation, AKT phosphorylation, Cdh11-/- wound healing model

    PMID:31930567

    Open questions at the time
    • Mechanism of sensitization (affinity vs trafficking) not defined
    • Single-lab study
  24. 2022 High

    Quantitatively dissected dimer-specific receptor dynamics, showing PDGFRβ homodimers signal more strongly and recycle preferentially versus PDGFRα.

    Evidence BiFC cell lines, live imaging, phospho-ERK/AKT blots, proliferation/migration and clathrin inhibition

    PMID:35946433

    Open questions at the time
    • Structural basis of faster dimerization not defined
    • Heterodimer dynamics less fully characterized
  25. 2022 High

    Comprehensively established PFBC-associated PDGFRB variants as loss-of-function across multiple distinct mechanisms including abolished ligand binding.

    Evidence Transfection of 13 variants with expression, PDGF-BB binding, kinase, and signaling assays

    PMID:34494111

    Open questions at the time
    • Link from receptor hypofunction to brain calcification mechanism unresolved
    • No in vivo validation
  26. 2023 High

    Validated in vivo that aneurysm-associated PDGFRB mutations drive arterial dilatation through constitutive ERK/NF-κB and inflammatory signaling, reversible by kinase inhibition.

    Evidence Exome/deep sequencing, signaling assays, spatial transcriptomics, viral mutant overexpression mouse model, sunitinib rescue

    PMID:37315111

    Open questions at the time
    • Cell-type origin of inflammatory program not fully resolved
    • Translational dosing not established

Open questions

Synthesis pass · forward-looking unresolved questions
  • How distinct loss-of-function PDGFRB hypofunction states mechanistically cause brain calcification, and how dimer/partner-specific signaling outputs are selected to drive divergent fibrotic, regenerative, and transforming programs, remain unresolved.
  • No mechanistic link from receptor hypofunction to calcium deposition
  • Structural basis of partner-biased signaling (integrin α11, cadherin-11) undefined
  • Endosomal compartment determinants of signal duration vs degradation incompletely mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 4 GO:0001618 virus receptor activity 2 GO:0060089 molecular transducer activity 2 GO:0140657 ATP-dependent activity 2 GO:0048018 receptor ligand activity 1
Localization
GO:0005886 plasma membrane 3 GO:0005768 endosome 2
Pathway
R-HSA-1643685 Disease 7 R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-8953854 Metabolism of RNA 1
Partners
ACK1CDH11EBP50ITGA11PDGFRARHOBSTAT3

Evidence

Reading pass · 31 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2022 PDGFRβ homodimers dimerize more quickly and show increased autophosphorylation compared to PDGFRα homodimers in response to PDGF ligand. PDGFRα homodimers are trafficked and degraded more quickly after activation, whereas PDGFRβ homodimers are more likely to be recycled back to the cell membrane. PDGFRβ homodimer activation results in greater amplitude of phospho-ERK1/2 and phospho-AKT signaling, as well as increased proliferation and migration. Inhibition of clathrin-mediated endocytosis alters cellular trafficking and downstream signaling, particularly for PDGFRα homodimers. Bimolecular fluorescence complementation (BiFC) cell lines stably expressing C-terminal PDGFR fusions; live imaging; western blot for phospho-ERK1/2 and phospho-AKT; proliferation and migration assays; clathrin inhibitor experiments Journal of cell science High 35946433
2007 RhoB GTPase is required for PDGFR-β trafficking to a perinuclear late endosomal compartment and for downstream nuclear localization of Src, Akt, and ERK in vascular smooth muscle cells. In RhoB knockout cells, PDGF-stimulated PDGFR-β trafficking to late endosomes is abrogated, phosphorylation of Akt and ERK1/2 is reduced, and cell proliferation in response to PDGF is lost. Restoring RhoB expression rescues these defects. RhoB knockout mouse-derived vascular smooth muscle cells; subcellular fractionation/immunofluorescence for PDGFR-β trafficking; nuclear fractionation for Src/Akt/ERK; phosphorylation western blots; proliferation assays; RhoB re-expression rescue experiments Arteriosclerosis, thrombosis, and vascular biology High 17951322
2014 PDGFR-β activation promotes glioma tumorigenesis via a PDGFR-β/ACK1/AKT signaling axis. PDGF treatment promotes formation of complexes containing PDGFR-β and ACK1; PDGFR-β phosphorylates ACK1 at Y635, which is required for sequential AKT activation. PDK1 interacts with ACK1 during PDGF stimulation (requiring T325 of ACK1), and this interaction is required for ACK1 binding to PDGFR-β. ACK1 Y635F or T325A mutants abolish PDGFR-β-induced AKT activation, β-catenin nuclear translocation, and cyclin D1 expression, blocking cell cycle progression and tumorigenesis. Co-immunoprecipitation; site-directed mutagenesis of ACK1 (Y635F, T325A); dominant-negative and overexpression constructs; western blot for phosphorylation; cell cycle and proliferation assays; in vivo glioblastoma patient sample analysis International journal of cancer High 25257795
2019 Integrin α11 interacts physically with PDGFRβ in a ligand-dependent manner in cancer-associated fibroblasts and promotes JNK activation downstream of PDGFRβ, leading to tenascin C production and CAF-induced tumor cell invasion. Pharmacological inhibition of PDGFRβ or JNK impaired tumor cell invasion induced by integrin α11-positive CAFs. Co-immunoprecipitation of integrin α11 with PDGFRβ; pharmacological inhibition of PDGFRβ and JNK; invasion assays with multiple human and murine CAF subpopulations; MMTV-PyMT mouse model with integrin α11 deficiency The Journal of clinical investigation High 31287804
2019 Somatic activating PDGFRB variants (predominantly in the juxtamembrane domain or kinase activation loop) found in fusiform cerebral aneurysms confer non-ligand-dependent auto-phosphorylation with downstream activation of ERK, SRC, and AKT. These variant receptors are responsive to the kinase inhibitor sunitinib. Paired-sample exome sequencing; in vitro expression of discovered variants with phosphorylation assays; western blot for downstream signaling (ERK, SRC, AKT); sunitinib inhibition American journal of human genetics Medium 31031011
2023 Somatic PDGFRB mutations identified in intracranial aneurysms constitutively activate ERK and NF-κB signaling, enhance cell motility, and induce inflammation-related gene expression. Virus-mediated overexpression of mutant PDGFRB induced fusiform-like dilatation of the basilar artery in mice, blocked by systemic sunitinib administration. Whole-exome and targeted deep sequencing; in vitro signaling assays; spatial transcriptomics; in vivo mouse arterial dilatation model with viral overexpression; tyrosine kinase inhibitor treatment Science translational medicine High 37315111
2014 PDGFRB mutations associated with idiopathic basal ganglia calcification (IBGC) impair receptor signaling. The L658P mutant has no kinase activity and fails to activate any downstream pathways. The R987W mutant activates Akt and MAP kinases but does not induce STAT3 phosphorylation and fails to phosphorylate phospholipase Cγ, and is more rapidly degraded upon PDGF binding. Transfection of mutant receptors in cell lines; kinase activity assays; phosphorylation western blots for multiple downstream effectors (Akt, MAPK, STAT3, PLCγ); receptor degradation assays Journal of cellular and molecular medicine High 25292412
2022 PDGFRB variants associated with primary familial brain calcification (PFBC) cause receptor loss of function through distinct mechanisms: some cause complete loss of tyrosine kinase activity; the p.Pro154Ser variant decreases receptor expression and abolishes PDGF-BB ligand binding; others show partial loss of function through reduced expression or reduced signaling. These findings establish that PFBC-associated PDGFRB variants result in loss-of-function rather than gain-of-function. Transfection of mutant receptors in cell lines; receptor expression assays; PDGF-BB binding assays; kinase activity assays; signaling/mitogenic activity assays Human molecular genetics High 34494111
2017 The EBF1-PDGFRB fusion protein causes multimerization and autophosphorylation, activates STAT5 signaling, and confers IL-7-independent cell proliferation. The transmembrane (TM) domain of PDGFRB is critically required for nuclear export of EBF1 and loss of EBF1 transcription factor function; deletion of the TM domain partially rescues EBF1 function and restores IL-7 dependence without requiring kinase inhibition. EBF1-PDGFRB synergizes with loss of IKAROS function to drive fully penetrant B-ALL in vivo. Mutagenesis of TM domain; STAT5 phosphorylation assays; cytokine-independence proliferation assays; in vivo B-ALL mouse model; co-expression with IKAROS loss-of-function Leukemia High 28555080
2017 JUN and JUNB transcription factors directly regulate PDGFRB expression in NPM-ALK-driven lymphoma cells. Therapeutic inhibition of PDGFRB markedly prolonged survival of NPM-ALK transgenic mice. Transcriptional regulation analysis; mouse model of NPM-ALK lymphomagenesis; PDGFRB inhibitor treatment; survival analysis in transgenic mice Nature medicine Medium 23064464
2012 PDGFR-β/PI3K/Akt signaling pathway mediates PDGF-BB-induced proliferation, migration, and angiogenesis in endothelial progenitor cells. Pharmacological inhibition of PDGFR kinase (AG1295), PI3K (LY294002), or Akt (sc-221226) each blocked these PDGF-BB-induced phenotypes. PDGFR-β overexpression in EPCs; inhibitor treatments (AG1295, LY294002, Akt inhibitor); proliferation, migration (scratch assay), and tube formation/angiogenesis assays PloS one Medium 22355314
2019 PDGFR-β signaling promotes cardiomyocyte proliferation and heart regeneration through the PI3K/p-Akt pathway, which upregulates EZH2. Conditional knockout of Ezh2 blocks cardiomyocyte proliferation and H3K27me3 modification during neonatal heart regeneration with Ink4a/Arf upregulation, even in mice with myocyte-specific PDGFR-β activation. AAV9-mediated delivery of activated PDGFR-β enhances adult heart regeneration and systolic function. Conditional PDGFR-β activation in cardiomyocytes (transgenic mouse); conditional Ezh2 knockout; RNA sequencing; H3K27me3 ChIP; AAV9 gene therapy; cardiac functional analysis Cell reports High 31340157
2020 PDGFR-β activation alone in renal mesenchymal cells is sufficient to drive progressive kidney fibrosis, causing mesangial cell pathological proliferation and phenotypic switch toward myofibroblasts, resulting in mesangioproliferative glomerulonephritis and interstitial fibrosis. PDGFR inhibition reversed fibrosis, more effectively in the tubulointerstitium than glomeruli. Transgenic mice with PDGFR-β activation specifically in renal mesenchymal cells; histopathology; gene expression profiling; PDGFR inhibitor treatment EMBO molecular medicine High 31943786
2004 c-Myc binds to the proximal promoter of the PDGFRB gene in proliferating rat fibroblasts (demonstrated by chromatin immunoprecipitation). Promoter-binding and transcriptional repression of PDGFRB by c-Myc are separable activities: c-Myc mutants unable to repress PDGFRB still bind its promoter. Trichostatin A (TSA, HDAC inhibitor) blocks Myc repression of PDGFRB without disrupting promoter binding, indicating that repression requires a post-binding, HDAC-dependent step. Chromatin immunoprecipitation (ChIP) in rat fibroblasts; c-Myc mutant constructs (dBR, d106-143); PDGFRB mRNA expression assays; TSA treatment Nucleic acids research High 15226411
2017 Synectin regulates PDGFR-β and PDGFR-α through distinct mechanisms. For PDGFR-β, synectin knockdown reduces PDGFR-β transcription through histone modifications at the PDGFR-β promoter (dependent on p300 histone acetyltransferase, shown by chromatin IP). For PDGFR-α, synectin protects it from autophagic degradation; site-directed mutagenesis revealed that ubiquitination of specific PDGFR-α lysine residues is responsible for its autophagic degradation. Synectin knockdown decreases PDGF-dependent migration and proliferation of hepatic stellate cells. Synectin knockdown; chromatin IP of PDGFR-β promoter; mRNA sequencing; site-directed mutagenesis of PDGFR-α lysine ubiquitination sites; autophagy assays; migration and proliferation assays; mouse liver fibrosis model with HSC-specific synectin deletion JCI insight High 29263300
2008 PDGFRβ functions as a binding receptor for Chlamydia trachomatis at the cell surface. Inhibition of PDGFRβ by RNA interference or PDGFRβ-neutralizing antibodies significantly reduces bacterial binding. PDGFRβ is phosphorylated upon infection and recruited to the site of bacterial attachment. Bacterial internalization can occur independently through activation of Abl kinase, converging on phosphorylation of the Rac GEF Vav2 and actin nucleators WAVE2 and Cortactin. RNAi screen in Drosophila S2 cells; siRNA knockdown of PDGFRβ in mammalian cells; neutralizing antibody against PDGFRβ; bacterial binding and internalization assays; phosphorylation assays PLoS pathogens Medium 18369471
2004 PDGF-BB and its receptor PDGFR-β are expressed in the developing mouse testis, with PDGFR-β specifically present on mesonephric p75NTR+ mesenchymal cells. PDGF-BB promotes migration and proliferation of these cells in vitro, and these responses involve MAPK and PI3K pathways (blocked by U0126 and LY294002, respectively). Addition of PDGF-BB to serum-free medium is sufficient to allow male urogenital ridge organ cultures to form testis cords. Immunomagnetic cell isolation; in vitro migration and proliferation assays; pharmacological inhibition of MAPK (U0126) and PI3K (LY294002); organ culture experiments; expression analysis Journal of cell science Medium 14996938
2001 Both PDGFRα and PDGFRβ promote fibroblast (NIH 3T3) cell migration, and their effects are additive. PDGFRβ activation alone (via dominant-negative α-PDGFR or antisense α-PDGFR constructs) is sufficient to induce NIH 3T3 cell migration, but with lower efficiency than co-activation of both receptors. This differs from smooth muscle cells where PDGFRα antagonizes PDGFRβ-induced migration. Dominant-negative PDGFRα and antisense PDGFRα constructs in NIH 3T3 cells; cell migration assays with PDGF-AA and PDGF-BB Biochemical and biophysical research communications Medium 11401517
2008 PDGFR-β receptor (but not PDGFRα) is essential for vascular stability/pericyte recruitment in vivo. Anti-PDGFRβ neutralizing antibody significantly blocks PDGF-AB/FGF-2-induced vessel stability in a mouse cornea angiogenesis model, while PDGF-AA/FGF-2 (which does not bind PDGFRβ) cannot stabilize vessels. Mouse cornea angiogenesis model; anti-PDGFRβ neutralizing antibody; comparison of PDGF-AA/FGF-2 vs PDGF-AB/FGF-2 combinations; rat ischemic hind-limb model; immunohistochemistry for pericytes FASEB journal Medium 18827023
2021 Pdgfrb signaling is conserved in zebrafish for vascular mural cell development. pdgfrb mutant zebrafish lack brain pericytes and show anatomically selective loss of vascular smooth muscle coverage (similar to mouse), but without early circulatory defects. At juvenile stages, pdgfrb mutants develop cranial hemorrhage and vessel dilation. pdgfrb mutants also display glomerular structural defects but normal hepatic stellate cell development, and defective mural cell investment on coronary vessels. pdgfb and pdgfrb mutant zebrafish genetic analysis; histology; vascular imaging; phenotypic characterization across developmental stages Developmental biology Medium 34310924
2017 PDGFR-β/STAT3 signaling is a key pathway inhibited by the combination of melatonin and sorafenib in pancreatic cancer cells. Proximity ligation assay and immunoprecipitation confirmed PDGFR-β interaction with STAT3 in this context. Phospho-RTK array; phospho-tyrosine kinase array; western blotting; proximity ligation assay; immunoprecipitation; PDAC xenograft model Cellular physiology and biochemistry Low 29953970
2016 Pdgfra and pdgfrb genetically interact during palatogenesis in zebrafish and mouse. pdgfrb single mutants have no craniofacial defect, but pdgfra;pdgfrb double mutants show significantly more severe palatal defects than pdgfra single mutants, demonstrating genetic interaction. Time-lapse confocal imaging shows failure of proper neural crest condensation in double mutants. Both receptors are expressed by neural crest in pharyngeal arches. Zebrafish and mouse genetic mutant analysis; pharmacological Pdgf pathway inhibition; time-lapse confocal imaging; proliferation and cell death assays Developmental dynamics Medium 26971580
2014 miR-34a directly targets the 3'-UTR of PDGFR-β mRNA (confirmed by dual-luciferase assay), inhibiting PDGFR-β protein expression at a post-transcriptional level, suppressing Ras/MAPK signaling, and downregulating cyclin D1, CDK4/CDK6, cyclin E, and CDK2, resulting in G0/G1 cell cycle arrest in renal mesangial cells. Dual-luciferase 3'-UTR reporter assay; miR-34a overexpression/inhibition; cell cycle analysis; western blot for PDGFR-β, phospho-MEK1, cyclins; anti-Thy1 nephritis rat model Cellular and molecular life sciences Medium 24638095
1999 The TEL/PDGFR-β (T/P) fusion protein activates JNK/SAPK signaling through the PDGFR-β tyrosine kinase activity. A specific PDGFR-β kinase inhibitor abrogates JNK/SAPK activation. A dominant-negative MKK4 mutant prevents T/P-induced JNK/SAPK activation and decreases T/P-mediated apoptosis. PI3K inhibition potentiates T/P-mediated JNK/SAPK activation and cell death, indicating that PI3K promotes survival downstream of T/P. Stable Ba/F3 cell expression of T/P fusion; PDGFR-β kinase inhibitor treatment; dominant-negative MKK4 expression; PI3K inhibitor (LY294002) treatment; JNK/SAPK activity assays; apoptosis assays Oncogene Medium 10445851
2020 Cadherin-11 (CDH11) binds directly to PDGFRβ and enhances cellular sensitivity to PDGF-BB by 10- to 100-fold, resulting in rapid and sustained AKT phosphorylation and promoting cell proliferation and tissue regeneration. Wound healing in Cdh11-/- mice is severely compromised, with decreased proliferation, AKT phosphorylation, and extracellular matrix synthesis. Co-immunoprecipitation of CDH11 with PDGFRβ; dose-response proliferation assays; AKT phosphorylation western blots; Cdh11-/- mouse wound healing model FASEB journal Medium 31930567
2017 GLI2 directly induces PDGFRB expression in gastric cancer cells by binding to the PDGFRB promoter region, confirmed by dual-luciferase assay. GLI2 or PDGFRB knockdown produces similar effects on reducing spheroid colony formation and CSC-related gene expression (CD44, Nanog, Oct4), placing PDGFRB downstream of GLI2 in a Hedgehog-driven CSC pathway. Dual-luciferase reporter assay for GLI2 binding to PDGFRB promoter; GLI2 overexpression; GLI2 and PDGFRB shRNA knockdown; spheroid colony formation assays; Western blot for CSC markers European review for medical and pharmacological sciences Low 28975979
2003 PDGFR-alpha and PDGFR-beta function as receptors for adeno-associated virus type 5 (AAV-5) transduction. Expression of PDGFR-alpha and PDGFR-beta correlated significantly with AAV-5 transduction permissiveness across 43 cell lines. The tropism of AAV-5 in vivo correlated with PDGFR-alpha expression pattern. cDNA microarray expression profiling across 43 cell lines categorized as permissive/nonpermissive; correlation analysis; follow-up experiments confirming PDGFR role in AAV-5 transduction Nature medicine Medium 14502277
2017 PDGFRB gain-of-function mutations (in transmembrane, juxtamembrane, and kinase domains) activate receptor signaling in the absence of ligand and transform fibroblasts in sporadic infantile myofibromatosis. All but one mutant (D850V) were sensitive to imatinib; D850V was inhibited by dasatinib and ponatinib. Sequencing of PDGFRB in myofibromatosis samples; functional assays of receptor activation (ligand-independent signaling); fibroblast transformation assays; tyrosine kinase inhibitor sensitivity testing Human molecular genetics Medium 28334876
2019 All PDGFRB gain-of-function mutations found in pediatric myofibroma are associated with ligand-independent receptor activation, and all but one were sensitive to imatinib at clinically relevant concentrations. Targeted deep sequencing of PDGFRB; functional characterization of mutations for gain-of-function; imatinib sensitivity assays JAMA dermatology Medium 31017643
2016 PDGFR-β-positive cells are the primary site of erythropoietin (EPO) production in the kidney. HIF-2α (not HIF-1α) is the essential transcription factor triggering EPO expression in PDGFR-β+ cells. Deletion of HIF-2α alone or combined with Vhl deletion in PDGFR-β+ cells abolishes EPO expression and reverses elevated hematocrit. Conditional Vhl deletion in PDGFR-β+ cells (transgenic mouse); HIF-1α and HIF-2α conditional deletion in PDGFR-β+ cells; plasma EPO and mRNA measurements; prolyl-hydroxylase inhibitor treatment Pflugers Archiv High 27220347
2003 NF2/Merlin overexpression in schwannoma cells accelerates internalization and degradation of PDGFR from the cell surface, inhibiting MAPK (Erk1/2) and PI3K (Akt) signaling downstream of PDGF. An interaction between PDGFR and EBP50/NHE-RF was found in primary human schwannoma tissue. Adenoviral NF2 gene transfer; receptor internalization assays; phosphorylation western blots (Erk1/2, Akt); co-expression analysis in schwannoma tissue International journal of oncology Low 14612918

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1991 Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene 310 1656368
2003 Pdgfr-alpha mediates testis cord organization and fetal Leydig cell development in the XY gonad. Genes & development 288 12651897
2006 Autocrine PDGFR signaling promotes mammary cancer metastasis. The Journal of clinical investigation 287 16741576
2003 Identification of PDGFR as a receptor for AAV-5 transduction. Nature medicine 272 14502277
2012 Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology 244 23255827
2017 The PDGF/PDGFR pathway as a drug target. Molecular aspects of medicine 225 29137923
2022 Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. International journal of biological macromolecules 178 35074329
2012 Over-expression of PDGFR-β promotes PDGF-induced proliferation, migration, and angiogenesis of EPCs through PI3K/Akt signaling pathway. PloS one 177 22355314
2019 Stromal integrin α11 regulates PDGFR-β signaling and promotes breast cancer progression. The Journal of clinical investigation 139 31287804
2018 The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological research 138 29408302
2008 Differential roles of PDGFR-alpha and PDGFR-beta in angiogenesis and vessel stability. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 133 18827023
2013 A recurrent PDGFRB mutation causes familial infantile myofibromatosis. American journal of human genetics 123 23731537
2005 Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 120 15939344
2008 RNA interference screen identifies Abl kinase and PDGFR signaling in Chlamydia trachomatis entry. PLoS pathogens 119 18369471
2013 Progenitor cells identified by PDGFR-alpha expression in the developing and diseased human heart. Stem cells and development 106 23391309
2005 Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer research 100 15705896
2012 PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature medicine 99 23064464
2018 PDGF/PDGFR axis in the neural systems. Molecular aspects of medicine 88 29409855
2008 PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 82 18679424
2017 PDGFRB gain-of-function mutations in sporadic infantile myofibromatosis. Human molecular genetics 80 28334876
2003 Overexpression of the NF2 gene inhibits schwannoma cell proliferation through promoting PDGFR degradation. International journal of oncology 78 14612918
2001 Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration. Biochemical and biophysical research communications 77 11401517
2019 PDGFR-β Signaling Regulates Cardiomyocyte Proliferation and Myocardial Regeneration. Cell reports 69 31340157
2020 Dysregulated mesenchymal PDGFR-β drives kidney fibrosis. EMBO molecular medicine 63 31943786
2016 Role of PDGF-D and PDGFR-β in neuroinflammation in experimental ICH mice model. Experimental neurology 59 27302678
2007 RhoB regulates PDGFR-beta trafficking and signaling in vascular smooth muscle cells. Arteriosclerosis, thrombosis, and vascular biology 57 17951322
2007 Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 56 17431412
2021 Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2. American journal of clinical pathology 55 33367495
2019 Association of PDGFRB Mutations With Pediatric Myofibroma and Myofibromatosis. JAMA dermatology 54 31017643
2018 PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood 54 29434033
2021 PDGF-PDGFR network differentially regulates the fate, migration, proliferation, and cell cycle progression of myogenic cells. Cellular signalling 52 33971280
2003 Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorganic & medicinal chemistry 51 12670652
2013 Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. International journal of laboratory hematology 50 23489324
2014 Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling. Journal of cellular and molecular medicine 49 25292412
2021 TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the PDGFRB/PI3K/AKT signaling pathway. Journal of translational medicine 48 33731124
2018 Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. iScience 47 30384135
2017 Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of hematology 46 28725989
2009 PDGF-C and -D and their receptors PDGFR-alpha and PDGFR-beta in atherosclerotic human arteries. European journal of clinical investigation 44 19292888
2011 Targeting PDGFR-β in Cholangiocarcinoma. Liver international : official journal of the International Association for the Study of the Liver 42 22133064
2015 Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. American journal of clinical pathology 41 26276769
2008 Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. Journal of cellular and molecular medicine 41 19175693
2019 Somatic PDGFRB Activating Variants in Fusiform Cerebral Aneurysms. American journal of human genetics 39 31031011
2016 Erythropoietin production by PDGFR-β(+) cells. Pflugers Archiv : European journal of physiology 39 27220347
2012 Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 39 22865780
2014 miR-34a regulates mesangial cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cellular and molecular life sciences : CMLS 36 24638095
2020 Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell death and differentiation 35 31969692
2017 Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-oncology 35 28486691
2016 Pdgfra and Pdgfrb genetically interact during craniofacial development. Developmental dynamics : an official publication of the American Association of Anatomists 35 26971580
2019 PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. Oncogene 34 30874597
2014 PDGFR-β-activated ACK1-AKT signaling promotes glioma tumorigenesis. International journal of cancer 34 25257795
2023 PDGFRB and NOTCH3 Mutations are Detectable in a Wider Range of Pericytic Tumors, Including Myopericytomas, Angioleiomyomas, Glomus Tumors, and Their Combined Tumors. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 33 36788105
2022 PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. International journal of molecular sciences 32 35409263
2018 Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 32 29953970
2018 PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy. Clinical sarcoma research 31 30083310
2023 PDGFR in PDGF-BB/PDGFR Signaling Pathway Does Orchestrates Osteogenesis in a Temporal Manner. Research (Washington, D.C.) 30 37223474
2016 Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 30 26857280
2011 Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-β) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clinical lung cancer 30 21729646
2017 GLI2 induces PDGFRB expression and modulates cancer stem cell properties of gastric cancer. European review for medical and pharmacological sciences 29 28975979
2015 Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. PloS one 29 26247786
2021 Conserved and context-dependent roles for pdgfrb signaling during zebrafish vascular mural cell development. Developmental biology 28 34310924
2013 Specific analysis of KIT and PDGFR-alpha expression and mutational status in Merkel cell carcinoma. Journal of cutaneous pathology 27 23621836
2024 Current status of drugs targeting PDGF/PDGFR. Drug discovery today 26 38663580
2024 IGF2BP2-modified circular RNA circCHD7 promotes endometrial cancer progression via stabilizing PDGFRB and activating JAK/STAT signaling pathway. Cancer gene therapy 26 38778089
2018 Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-α and PDGFR-β. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 26 30007969
2017 Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Molecular cancer therapeutics 26 28619758
2010 Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs : the investigational drugs journal 26 20432191
2007 Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Hepato-gastroenterology 26 18265649
2016 PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget 25 27764787
2011 Expression of PDGFR-β and Kit in canine anal sac apocrine gland adenocarcinoma using tissue immunohistochemistry. Veterinary and comparative oncology 25 22235855
2023 Research progress on the role of PDGF/PDGFR in type 2 diabetes. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 24 37290188
2017 Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis. Leukemia 24 28555080
2005 Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas. Cellular oncology : the official journal of the International Society for Cellular Oncology 24 16373964
2019 Autophagy induction and PDGFR-β knockdown by siRNA-encapsulated nanoparticles reduce chlamydia trachomatis infection. Scientific reports 23 30718536
2004 Promoter-binding and repression of PDGFRB by c-Myc are separable activities. Nucleic acids research 23 15226411
2008 Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases. Future oncology (London, England) 22 18922118
2019 miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling. Scientific reports 21 30824765
2018 CD140b (PDGFRβ) signaling in adipose-derived stem cells mediates angiogenic behavior of retinal endothelial cells. Regenerative engineering and translational medicine 21 30976657
2017 Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma. Veterinary and comparative oncology 21 28884928
2017 Synectin promotes fibrogenesis by regulating PDGFR isoforms through distinct mechanisms. JCI insight 21 29263300
2023 Increased PDGFRB and NF-κB signaling caused by highly prevalent somatic mutations in intracranial aneurysms. Science translational medicine 20 37315111
2014 Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes, chromosomes & cancer 20 24772479
2010 CD34+CD140b+ cells and circulating CXCL12 correlate with the angiographically assessed severity of cardiac allograft vasculopathy. European heart journal 20 21036775
2004 Expression and role of PDGF-BB and PDGFR-beta during testis morphogenesis in the mouse embryo. Journal of cell science 20 14996938
2017 Insulin-Mediated Signaling Facilitates Resistance to PDGFR Inhibition in Proneural hPDGFB-Driven Gliomas. Molecular cancer therapeutics 19 28138037
1999 The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. Oncogene 19 10445851
2022 PDGFR dimer-specific activation, trafficking and downstream signaling dynamics. Journal of cell science 18 35946433
2021 Single-cell RNA sequencing of cultured human endometrial CD140b+CD146+ perivascular cells highlights the importance of in vivo microenvironment. Stem cell research & therapy 18 34051872
2020 Cadherin-11 binds to PDGFRβ and enhances cell proliferation and tissue regeneration via the PDGFR-AKT signaling axis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18 31930567
2020 Anti-cancer potential of persimmon (Diospyros kaki) leaves via the PDGFR-Rac-JNK pathway. Scientific reports 18 33093618
2024 Roles of PDGF/PDGFR signaling in various organs. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 16 39482238
2023 Chronological and Replicative Aging of CD51+/PDGFR-α+ Pulp Stromal Cells. Journal of dental research 16 36919905
2018 Influence of amygdalin on PDG, IGF and PDGFR expression in HSC-T6 cells. Experimental and therapeutic medicine 16 29556259
2014 Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma. Neurosurgical review 16 25323095
2022 Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents. Current medicinal chemistry 15 33655823
2022 Distinct functional classes of PDGFRB pathogenic variants in primary familial brain calcification. Human molecular genetics 15 34494111
2021 Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. Annals of hematology 15 34859285
2017 mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma. Human pathology 15 28506734
2021 Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. The Journal of clinical endocrinology and metabolism 14 34302727
2010 FIP1L1/PDGFR alpha-associated systemic mastocytosis. International archives of allergy and immunology 14 20523072
2006 Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis. Oncogene 14 16878155

Missed literature

Know a paper Affinage missed for PDGFRB? Flag it for the maintainers and the community.

No submissions yet.